{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05291234",
            "orgStudyIdInfo": {
                "id": "M22-721"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-500691-59-00",
                    "type": "OTHER",
                    "domain": "EU CT"
                }
            ],
            "organization": {
                "fullName": "AbbVie",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer's Disease",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "a-study-to-assess-safety-of-abbv-and-how-intravenous-abbv-moves-through-body-and-affects-brain-amyloid-plaque-clearance-in-adult-participants-aged-years-with-early-alzheimer-s-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2031-03-26",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-03-26",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-21",
            "studyFirstSubmitQcDate": "2022-03-21",
            "studyFirstPostDateStruct": {
                "date": "2022-03-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AbbVie",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-916 is in treating early AD. Adverse events, change in disease activity, and how ABBV-916 moves through body of participants will be assessed.\n\nABBV-916 is an investigational drug being developed for the treatment of early AD. This study is conducted in 2 stages. Stage A is a multiple ascending dose study. There is a 1 in 4 chance that participants are assigned to receive placebo. Stage B is a proof-of-concept study. In Stage B, there is a 1 in 5 chance that participants will be assigned to receive placebo. The first 6 months of this study are \"double-blind,\" which means that neither the trial participant nor the study doctors know which treatments will be given. This will be followed by a 2-year extension period in which all participants will receive ABBV-916. Approximately 195 participants aged 50-90 years will be enrolled in about 90 sites across the world.\n\nParticipants will receive intravenous (IV) doses of ABBV-916 or placebo once every 4 weeks (Q4W) for 24 weeks and will be followed for an additional 16 weeks. Participants will have the option of participating in a 2-year, open-label, Extension Period receiving IV ABBV-916.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, magnetic resonance imaging (MRI), blood tests, checking for side effects and completing questionnaires."
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer's Disease (AD)"
            ],
            "keywords": [
                "Alzheimer's Disease (AD)",
                "Early Alzheimer's Disease",
                "ABBV-916"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 195,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Stage A: ABBV-916",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ABBV-916 for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.",
                    "interventionNames": [
                        "Drug: ABBV-916"
                    ]
                },
                {
                    "label": "Stage A: Placebo for ABBV-916",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Stage B: ABBV-916 Dose A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ABBV-916 Dose A for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.",
                    "interventionNames": [
                        "Drug: ABBV-916"
                    ]
                },
                {
                    "label": "Stage B: Placebo for ABBV-916",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive Placebo for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Stage B: ABBV-916 Dose B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive ABBV-916 Dose B for 24 weeks. Participants at the end of 24 weeks will have the option of participating in the 2-year Extension Period.",
                    "interventionNames": [
                        "Drug: ABBV-916"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ABBV-916",
                    "description": "Intravenous administration",
                    "armGroupLabels": [
                        "Stage A: ABBV-916",
                        "Stage B: ABBV-916 Dose A",
                        "Stage B: ABBV-916 Dose B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Intravenous administration",
                    "armGroupLabels": [
                        "Stage A: Placebo for ABBV-916",
                        "Stage B: Placebo for ABBV-916"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants Experiencing Adverse Events (AEs)",
                    "description": "An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.",
                    "timeFrame": "Up to approximately 160 weeks"
                },
                {
                    "measure": "Stage A: Maximum Observed Serum Concentration (Cmax) for Multiple Ascending Dose of ABBV-916",
                    "description": "Cmax of ABBV-916 will be determined.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage A: Time to Cmax (Tmax) for Multiple Ascending Dose of ABBV-916",
                    "description": "Tmax of ABBV-916 will be determined.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage A: Apparent Terminal Phase Elimination Rate Constant (\u03b2) of ABBV-916",
                    "description": "Apparent terminal phase elimination rate constant (\u03b2) of ABBV-916 will be determined.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage A: Terminal Phase Elimination Half-Life (t1/2) of ABBV-916",
                    "description": "T1/2 of ABBV-916 will be determined.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage A: Trough Serum Concentration (Ctrough) of ABBV-916 at the End of a Dosing Interval",
                    "description": "Ctrough of ABBV-916 will be determined.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage A: Area Under the Concentration-Time Curve (AUC) of ABBV-916",
                    "description": "AUC of ABBV-916 will be determined.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage A: Cerebrospinal Fluid (CSF) Concentration as a Measure of ABBV-916 Crossing the Blood Brain Barrier",
                    "description": "The central value for ratio of ABBV-916 concentration in cerebrospinal fluid (CSF) to that in serum will be estimated for evaluation of the fraction of ABBV-916 crossing the blood brain barrier.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage A: Percentage of Participants With Antidrug Antibodies (ADA) as a Measure of Immunogenicity Following Multiple Ascending Dose of ABBV-916",
                    "description": "Antidrug antibody (ADA) classification and titers for positive ADA samples will be determined.",
                    "timeFrame": "Up to approximately 24 weeks"
                },
                {
                    "measure": "Stage B: Change in Brain Amyloid Plaque Deposition (Amyloid Centiloid Value)",
                    "description": "Change from baseline in brain amyloid plaque deposition (amyloid centiloid value) is measured by amyloid positron emission tomography (PET) scan.",
                    "timeFrame": "Baseline (Week 0) through Week 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of Stage 3 or Stage 4 Alzheimer's disease (AD) based on the 2018 National Institute on Aging (NIA)-Alzheimer's Association (AA) Research Framework Criteria.\n\n  * Mini-Mental State Examination (MMSE) score of 20 to 28, inclusive, at Screening.\n  * Blood-based biomarker results with a value consistent with amyloid positron emission tomography (PET) positivity. The biomarker will be chosen by the sponsor and described in the Laboratory Manual. Biomarker results will not be required for eligibility if the participant has a positive Amyloid PET scan meeting the central reader criteria.\n* Amyloid PET scan results consistent with amyloid pathology.\n* Stage B: Participants must have a study partner who spends a minimum average of 10 hours per week with the participant.\n\nExclusion Criteria:\n\n* Significant pathological findings on brain MRI at screening including, but not limited to, evidence of vasogenic edema, 4 or more microhemorrhages, any macrohemorrhages, any superficial siderosis, or severe white matter disease.\n* Any anticoagulants or have a bleeding disorder that is not adequately controlled.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "maximumAge": "90 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ABBVIE CALL CENTER",
                    "role": "CONTACT",
                    "phone": "844-663-3742",
                    "email": "abbvieclinicaltrials@abbvie.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "ABBVIE INC.",
                    "affiliation": "AbbVie",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Tucson Neuroscience Research /ID# 244957",
                    "status": "COMPLETED",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85710-6152",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "Irvine Clinical Research /ID# 239469",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92614",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "Artemis Institute for Clinical Research - San Diego /ID# 244508",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92103-2204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Pacific Research Network, Inc. /ID# 244083",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Syrentis Clinical Research /ID# 239682",
                    "status": "RECRUITING",
                    "city": "Santa Ana",
                    "state": "California",
                    "zip": "92705",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.74557,
                        "lon": -117.86783
                    }
                },
                {
                    "facility": "Aventura Neurological Associates /ID# 243892",
                    "status": "RECRUITING",
                    "city": "Aventura",
                    "state": "Florida",
                    "zip": "33180",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Coordinator",
                            "role": "CONTACT",
                            "phone": "833-732-2484"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.95648,
                        "lon": -80.13921
                    }
                },
                {
                    "facility": "Charter Research - Lady Lake /ID# 244657",
                    "status": "RECRUITING",
                    "city": "Lady Lake",
                    "state": "Florida",
                    "zip": "32162",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.91749,
                        "lon": -81.92286
                    }
                },
                {
                    "facility": "JEM Research Institute /ID# 239122",
                    "status": "RECRUITING",
                    "city": "Lake Worth",
                    "state": "Florida",
                    "zip": "33462-1141",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.61708,
                        "lon": -80.07231
                    }
                },
                {
                    "facility": "ClinCloud - Maitland /ID# 244507",
                    "status": "RECRUITING",
                    "city": "Maitland",
                    "state": "Florida",
                    "zip": "32751",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.62778,
                        "lon": -81.36312
                    }
                },
                {
                    "facility": "ClinCloud LLC - Viera/Melbourne /ID# 240635",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Florida",
                    "zip": "32940-8288",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.08363,
                        "lon": -80.60811
                    }
                },
                {
                    "facility": "Merritt Island Medical Research /ID# 239495",
                    "status": "RECRUITING",
                    "city": "Merritt Island",
                    "state": "Florida",
                    "zip": "32952-3616",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53917,
                        "lon": -80.672
                    }
                },
                {
                    "facility": "Optimus U /ID# 245868",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33125-4013",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Finlay Medical Research /ID# 245996",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33126",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Allied Biomedical Res Inst Inc /ID# 244823",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33155",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Renstar Medical Research /ID# 240153",
                    "status": "RECRUITING",
                    "city": "Ocala",
                    "state": "Florida",
                    "zip": "34470",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.1872,
                        "lon": -82.14009
                    }
                },
                {
                    "facility": "K2 Medical Research - Ocoee /ID# 246849",
                    "status": "RECRUITING",
                    "city": "Ocoee",
                    "state": "Florida",
                    "zip": "34761-4547",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.56917,
                        "lon": -81.54396
                    }
                },
                {
                    "facility": "K2 Medical Research - Orlando - South Orlando Avenue /ID# 243919",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32751",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Charter Research - Winter Park /ID# 244778",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32803-1839",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Headlands Research - Orlando /ID# 239119",
                    "status": "RECRUITING",
                    "city": "Orlando",
                    "state": "Florida",
                    "zip": "32819",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Coordinator",
                            "role": "CONTACT",
                            "phone": "407-705-3471"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.53834,
                        "lon": -81.37924
                    }
                },
                {
                    "facility": "Neurology Associates Ormond Beach /ID# 245527",
                    "status": "RECRUITING",
                    "city": "Ormond Beach",
                    "state": "Florida",
                    "zip": "32174",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.28581,
                        "lon": -81.05589
                    }
                },
                {
                    "facility": "IMIC Inc. Medical Research /ID# 245900",
                    "status": "RECRUITING",
                    "city": "Palmetto Bay",
                    "state": "Florida",
                    "zip": "33157",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.62177,
                        "lon": -80.32477
                    }
                },
                {
                    "facility": "Alzheimer's Research and Treatment Center - Stuart /ID# 245477",
                    "status": "RECRUITING",
                    "city": "Stuart",
                    "state": "Florida",
                    "zip": "34997-5765",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.19755,
                        "lon": -80.25283
                    }
                },
                {
                    "facility": "Alzheimer's Research and Treatment Center - Wellington /ID# 245201",
                    "status": "RECRUITING",
                    "city": "Wellington",
                    "state": "Florida",
                    "zip": "33414",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Site Coordinator",
                            "role": "CONTACT",
                            "phone": "5612092400"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.65868,
                        "lon": -80.24144
                    }
                },
                {
                    "facility": "Premiere Research Institute - Palm Beach /ID# 240108",
                    "status": "RECRUITING",
                    "city": "West Palm Beach",
                    "state": "Florida",
                    "zip": "33407-3209",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.71534,
                        "lon": -80.05337
                    }
                },
                {
                    "facility": "Clinical Site Partners (CSP) - Orlando /ID# 245127",
                    "status": "RECRUITING",
                    "city": "Winter Park",
                    "state": "Florida",
                    "zip": "32789-4681",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.6,
                        "lon": -81.33924
                    }
                },
                {
                    "facility": "Conquest Research /ID# 243916",
                    "status": "RECRUITING",
                    "city": "Winter Park",
                    "state": "Florida",
                    "zip": "32789",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 28.6,
                        "lon": -81.33924
                    }
                },
                {
                    "facility": "Columbus Memory Center /ID# 245054",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Georgia",
                    "zip": "31909",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.46098,
                        "lon": -84.98771
                    }
                },
                {
                    "facility": "QUEST Research Institute /ID# 239459",
                    "status": "RECRUITING",
                    "city": "Farmington Hills",
                    "state": "Michigan",
                    "zip": "48334-2977",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.48531,
                        "lon": -83.37716
                    }
                },
                {
                    "facility": "Advanced Memory Research Institute of NJ /ID# 239533",
                    "status": "RECRUITING",
                    "city": "Toms River",
                    "state": "New Jersey",
                    "zip": "08755-5043",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95373,
                        "lon": -74.19792
                    }
                },
                {
                    "facility": "Keystone Clinical Studies LLC /ID# 239973",
                    "status": "COMPLETED",
                    "city": "Plymouth Meeting",
                    "state": "Pennsylvania",
                    "zip": "19462",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.10233,
                        "lon": -75.27435
                    }
                },
                {
                    "facility": "Clinical Trials of Texas, Inc /ID# 244917",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Re:Cognition Health - Fairfax VA /ID# 239501",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031-5207",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "https://www.abbvieclinicaltrials.com/study/?id=M22-721"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "CSR"
            ],
            "timeFrame": "For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/",
            "accessCriteria": "Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/",
            "url": "https://vivli.org/ourmember/abbvie/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "Canada",
                "Italy",
                "Japan",
                "Portugal",
                "Spain"
            ]
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4021",
                    "name": "Amyloidosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M29002",
                    "name": "Plaque, Amyloid",
                    "relevance": "LOW"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}